Synthetic Cathinones (Bath Salts): an Emerging Domestic Threat Cox Broadcasting

Total Page:16

File Type:pdf, Size:1020Kb

Synthetic Cathinones (Bath Salts): an Emerging Domestic Threat Cox Broadcasting U.S. Department of Justice National Drug Intelligence Center July 2011 Situation Report Product Number 2011-S0787-004 Synthetic Cathinones (Bath Salts): An Emerging Domestic Threat Cox Broadcasting. Cox Broadcasting. Executive Summary The National Drug Intelligence Center (NDIC) assesses with high confidence that the distribu- tion and abuse of synthetic cathinones will increase in the United States in the near term, pos- ing yet another challenge to U.S. law enforcement officials. Poison control centers and medical professionals around the country are increasingly reporting patients suffering adverse physical effects associated with abuse of these drugs, further compounding the problem. Available data and law enforcement reporting suggest increasing levels of synthetic cathinone availability and abuse, but such information is limited and precise levels are unknown. U.S. Cus- toms and Border Protection (CBP) currently tracks seizures of synthetic cathinones at U.S. ports of entry (POEs), but many synthetic cathinone products are disguised or mislabeled to impede detection. Because common field test kits, drug-detecting canines, and routine urine drug screens do not detect synthetic cathinones, law enforcement officials are challenged in interdicting such drugs and prosecuting their manufacturers and distributors. Synthetic Cathinones (Bath Salts): An Emerging Domestic Threat Synthetic cathinones, typically marketed as “bath salts” and “plant food,” are sold legally un- der various names (Ivory Wave, Blizzard, etc.) in most areas of the United States. The products are generally sold in retail establishments such as adult stores, independently owned convenience stores, gas stations, head shops, and skateboard shops. The products, as well as their raw chemi- cal components, are also sold on many Internet sites, including popular Internet auction sites. Ad- ditionally, synthetic cathinones have been sold by independent dealers as ecstasya—in powdered form, in single-component tablets and capsules, and in tablets and capsules containing cathinones combined with MDMA (3,4-methylenedioxymethamphetamine) or other illicit controlled sub- stances. Abusers typically ingest, inhale, inject, smoke, or snort (insufflate) the drugs to experi- ence stimulant effects similar to those induced by amphetamine. Manufacturers and distributors of synthetic cathinone products evade U.S. Drug Enforce- ment Administration (DEA) regulation and enforcement because synthetic cathinones are not scheduled under the Federal Controlled Substances Act (CSA). However, possession and dis- tribution of the synthetic cathinones may be prosecuted, albeit with greater difficulty, under the Federal Controlled Substance Analogue Enforcement Act of 1986 (as amended)b of the CSA. The availability and suitability of a prosecution under the analogue statute depends on the particular compound being trafficked and the facts of the case. Further, distributors deceptively market synthetic cathinone products as “not for human consumption” to evade U.S. Food and Drug Administration (FDA) scrutiny. Cathinone products that are introduced into interstate commerce and promoted as alternatives to illicit street drugs may be prosecutable under the Federal Food, Drug, and Cosmetic Act as unapproved new drugs and misbranded drugs. (See the offenses at 21 U.S.C. 331(a), (d) and penalties at 21 U.S.C. 333.)1 Additionally, members of the Congress have introduced legislation to nationally ban the sale of certain synthetic cathinones,c and, as of April 2011, all 50 states and the District of Columbia have introduced or announced plans to introduce legislation banning or restricting the distribution and posses- sion of certain synthetic cathinones and cathinone derivatives. As synthetic cathinones become more regulated, abusers will likely use the Internet with greater frequency to purchase cathi- none products, the raw chemicals used in their production, and products that contain cathi- nones not specifically prohibited by enacted legislation. a. Ecstasy tablets typically contain MDMA (3,4-methylenedioxymethamphetamine) but can contain various other drugs in place of or in combination with MDMA. Other drugs commonly identified in ecstasy include metham- phetamine, amphetamine, BZP (N-benzylpiperazine), and caffeine. b. The Federal Controlled Substance Analogue Enforcement Act, enacted in 1986 as Pub. L. 99-570, title I, subtitle E, provides: “[a] controlled substance analogue shall, to the extent intended for human consumption, be treated . as a controlled substance in Schedule I.” The term “controlled substance analogue” is defined as a substance: (i) the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule I or II; (ii) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II; or (iii) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II.” c. S. 409, the “Combating Dangerous Synthetic Stimulants Act of 2011”. 2 Product Number 2011-S0787-004 National Drug Intelligence Center Background Synthetic cathinones are central nervous system stimulants. They are chemically similar to cathinone, a Schedule I controlled substance that occurs naturally in the khat2 plant (Catha edulis). The category of synthetic cathinones includes a number of drugs, such as MDPV (3,4-methylenedioxypyrovalerone) and mephedrone (which have been identified by the FDA Office of Criminal Investigations in illicit “bath salt” products;3 see Appendix A) as well as N-methylcathinone (also known as methcathinone or cat),4 4-fluoromethcathinone (also known as flephedrone or 4-FMC),5 and 3,4-methylenedioxy-N-methylcathinone (also known as methylone, MDMC, bk-MDMA, or M1).6 NDIC uses the term synthetic cathinone products to refer to synthetic cathinones packaged as authentic commercial products. These products include purported beauty and household goods such as “bath salt” products sold as Bliss, Blizzard, Blue Silk, Charge+, Hurricane Charlie, Ivory Snow, Ivory Wave, Ocean Burst, Pure Ivory, Purple Wave, Red Dove, Snow Leopard, Star Dust, Vanilla Sky, White Dove, White Knight, White Rush, and White Lighten- ing.7 Synthetic cathinone products are also marketed as plant food/fertilizer, insect repellant, pond cleaner, and vacuum fresheners.8 Synthetic cathinones are commonly distributed in powder, crystal, and liquid forms, but they are also available and abused in tablet and capsule forms.9 Some synthetic cathinone tablets and capsules have been marketed by distributers as ecstasy—forensic laboratories analyzing seized ecstasy tablets have reported that some tablets contain synthetic cathinones, alone or in combination with other drugs.10 However, these tablets and capsules have not been marketed in retail outlets or on the Internet in conjunction with the more widely recognized “bath salts.”11 Abusers typically ingest, inhale, inject, smoke, or snort (insufflate) synthetic cathinone prod- ucts to experience effects similar to those of amphetamine abuse. Some abusers dissolve the drugs in water or other solvents and proceed to atomizei and inhale them, while others apply the solutions to their mucus membranes by placing drops in their eyes or spraying the solutions in their noses.12 The term synthetic cathinone products, as used in this report, is not meant to refer to legal pharmaceuticals. The prescription drugs bupropion (Zyban®, Wellbutrin®), diethylpropion (Tenuate®), and pyrovalerone (Centroton®) are legal synthetic cathinone products—diethyl- propion is a Schedule IV controlled substance, and pyrovalerone is a Schedule V controlled substance under the Federal CSA. i. Atomizers are devices that use heat, pressure, or vibration to convert a liquid into a vapor or an aerosol mist so it can be inhaled and absorbed through the lungs. Electronic cigarettes are a common type of atomizer that uses heat. Nebulizers—often used by individuals with respiratory disorders and diseases—use vibration or pressure. 3 Synthetic Cathinones (Bath Salts): An Emerging Domestic Threat Synthetic Cathinone Availability and Abuse NDIC assesses with high confidence that the availability of synthetic cathinone products in the United States is high. State and local law enforcement information indicates that synthetic cathinone products are readily available in retail establishments and over the Internet, and some local inde- pendent dealers sell the products. Synthetic cathinone products, most marketed as “bath salts,” are distributed across the country in small, independently owned retail establishments such as adult stores, independently owned convenience stores, gas stations, head shops, and skateboard shops.13 The products, as well as their raw chemical components, are also sold on many Inter- net sites, including popular Internet auction sites and global marketing sites.14 The products are typically “branded” under the names previously listed. Some local independent drug dealers also distribute the products directly to users.15 Available seizure information indicates that significant
Recommended publications
  • WELLBUTRIN SR Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION psychosis, hallucinations, paranoia, delusions, homicidal ideation, These highlights do not include all the information needed to use aggression, hostility, agitation, anxiety, and panic, as well as suicidal WELLBUTRIN SR safely and effectively. See full prescribing ideation, suicide attempt, and completed suicide. Observe patients information for WELLBUTRIN SR. attempting to quit smoking with bupropion for the occurrence of such symptoms and instruct them to discontinue bupropion and contact a WELLBUTRIN SR (bupropion hydrochloride) sustained-release tablets, healthcare provider if they experience such adverse events. (5.2) for oral use • Initial U.S. Approval: 1985 Seizure risk: The risk is dose-related. Can minimize risk by gradually increasing the dose and limiting daily dose to 400 mg. Discontinue if WARNING: SUICIDAL THOUGHTS AND BEHAVIORS seizure occurs. (4, 5.3, 7.3) See full prescribing information for complete boxed warning. • Hypertension: WELLBUTRIN SR can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during • Increased risk of suicidal thinking and behavior in children, treatment. (5.4) adolescents and young adults taking antidepressants. (5.1) • Activation of mania/hypomania: Screen patients for bipolar disorder and • Monitor for worsening and emergence of suicidal thoughts and monitor for these symptoms. (5.5) behaviors. (5.1) • Psychosis and other neuropsychiatric reactions: Instruct patients to contact a healthcare professional if such reactions occur. (5.6) --------------------------- INDICATIONS AND USAGE ---------------------------- • Angle-closure glaucoma: Angle-closure glaucoma has occurred in WELLBUTRIN SR is an aminoketone antidepressant, indicated for the patients with untreated anatomically narrow angles treated with treatment of major depressive disorder (MDD). (1) antidepressants.
    [Show full text]
  • Drug and Alcohol Prevention Programs Annual Notification
    MCCCD DRUG AND ALCOHOL PREVENTION PROGRAMS ANNUAL NOTIFICATION STATEMENT ON DRUG-FREE CAMPUSES In accordance with the Drug-Free Schools and Communities Act Amendments of 1989 (Act), the Maricopa County Community College District (MCCCD) is distributing this notification to all students and employees to inform them of MCCCD’s comprehensive program to prevent the use of illicit drugs and the abuse of alcohol. This notification summarizes MCCCD’s programs, resources, policies, and standards of conduct; discusses health risks; highlights treatment options; and provides an overview of sanctions. STANDARDS OF CONDUCT It is the goal and policy of Maricopa County Community College District to provide a drug-free environment for all college students and employees. To achieve this goal and to comply with federal law, MCCCD prohibits the unlawful sale, distribution, dispensation, possession, and use of controlled substances on MCCCD property or as part of any of its programs and/or activities. Students, faculty, staff and visitors of any MCCCD campus are advised to become familiar with federal, state and local laws regarding alcohol and other drugs in accordance with the campus location. Students, faculty, staff, and visitors on any MCCCD campus must: 1) abide by MCCCD policies regarding alcohol abuse and illicit drugs; 2) abide by local, state and federal laws regarding alcohol, drugs, and controlled substances; and 3) act to reduce the risks associated with the use and abuse of these substances. MCCCD students and employees are subject to all applicable drug and alcohol policies including, but not limited to: AR 2.4.7 – Abuse-Free Environment AR 4.13 – Use of Alcoholic Beverages See also the Auxiliary Services section for Tobacco-Free Environment and the ​ ​ ​ ​ Appendices/Student Section Medical Marijuana Act of the Administrative Regulations.
    [Show full text]
  • EL PASO INTELLIGENCE CENTER DRUG TREND Synthetic Stimulants Marketed As Bath Salts
    LAW ENFORCEMENT SENSITIVE EPIC Tactical Intelligence Bulletins EL PASO INTELLIGENCE CENTER DRUG TREND TACTICAL INTELLIGENCE BULLETIN EB11-16 ● Synthetic Stimulants Marketed as Bath Salts ● March 8, 2011 This document is the property of the Drug Enforcement Administration (DEA) and is marked Law Enforcement Sensitive (LES). Further dissemination of this document is strictly forbidden except to other law enforcement agencies for criminal law enforcement purposes. The following information must be handled and protected accordingly. Summary Across the United States, synthetic stimulants that are sold as “bath salts”¹ have become a serious drug abuse threat. These products are produced under a variety of faux brand names, and they are indirectly marketed as legal alternatives to cocaine, amphetamine, and Ecstasy (MDMA or 3,4-Methylenedioxymethamphetamine). Poison control centers nationwide have received hundreds of calls related to the side-effects of, and overdoses from, the use of these potent and unpredictable products. Numerous media reports have cited bath salt stimulant overdose incidents that have resulted in emergency room visits, hospitalizations, and severe psychotic episodes, some of which, have led to violent outbursts, self-inflicted wounds, and even suicides. A number of states have imposed emergency measures to ban bath salt stimulant products (or the chemicals in them) including Florida, Louisiana, North Dakota, and West Virginia; and similar measures are pending in Hawaii, Kentucky, Michigan, and Mississippi. A prominent U.S.
    [Show full text]
  • Concomitant Drugs Associated with Increased Mortality for MDMA Users Reported in a Drug Safety Surveillance Database Isaac V
    www.nature.com/scientificreports OPEN Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database Isaac V. Cohen1, Tigran Makunts2,3, Ruben Abagyan2* & Kelan Thomas4 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug– drug interactions. The goal of this study was to evaluate the risks due to MDMA ingestion alone or in combination with other common medications and drugs of abuse using the FDA drug safety surveillance data. To date, nearly one thousand reports of MDMA use have been reported to the FDA. The majority of these reports include covariates such as co-ingested substances and demographic parameters. Univariate and multivariate logistic regression was employed to uncover the contributing factors to the reported risk of death among MDMA users. Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants (bupropion, sertraline, venlafaxine and citalopram) and olanzapine demonstrated increased odds ratios for the reported risk of death. Future drug–drug interaction clinical trials should evaluate if any of the other drug–drug interactions described in our results actually pose a risk of morbidity or mortality in controlled medical settings. 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Adminis- tration (FDA) for the treatment of posttraumatic stress disorder (PTSD). During the past two decades, “ecstasy” was illegally distributed and is purported to contain MDMA, but because the market is unregulated this “ecstasy” may actually contain adulterants or no MDMA at all1.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • Bath Salts and Synthetic Marijuana: an Emerging Threat by Rommie L
    Continuing Education Course Bath Salts and Synthetic Marijuana: An Emerging Threat BY ROMMIE L. DUCKWORTH TRAINING THE FIRE SERVICE FOR 135 YEARS To earn continuing education credits, you must successfully complete the course examination. The cost for this CE exam is $25.00. For group rates, call (973) 251-5055. Bath Salts and Synthetic Marijuana: An Emerging Threat Educational Objectives On completion of this course, students will 1) Define the term “Designer Drug”. 3) Determine what constitutes Bath Salts, and their effects. 2) Learn how regulation is not inhibiting the production of 4) Determine what constitutes Synthetic Marijuana, and its designer drugs. effects BY ROMMIE L. DUCKWORTH emergency responders, and healthcare providers. Designer drugs are chemical compounds that are newly created, modi- April 5, 2011. Spanaway, Washington: Medic and Army Ser- fied, or repurposed to provide abusers with effects similar to geant Dave Stewart, high on bath salts bought at a local pipe currently illegal recreational drugs. They are often relatively shop, killed himself and his wife during a police pursuit. Their five-year-old son was also found dead in the car. easy to make and, because of their ever-changing ingredient list, are also extremely difficult to regulate. August 21, 2011. Bowling Green, Kentucky: Teenager Ashley The term “designer drugs” originated in the 1980s, but Stillwell became paralyzed while smoking 7H, a form of syn- the idea of marketing legal chemical combinations related thetic marijuana, with her friends. She lay on the floor, helpless, to regulated or banned drugs dates back to the 1920s. Such as her friends discussed what to do, including how to dispose of her body.
    [Show full text]
  • FSI-D-16-00226R1 Title
    Elsevier Editorial System(tm) for Forensic Science International Manuscript Draft Manuscript Number: FSI-D-16-00226R1 Title: An overview of Emerging and New Psychoactive Substances in the United Kingdom Article Type: Review Article Keywords: New Psychoactive Substances Psychostimulants Lefetamine Hallucinogens LSD Derivatives Benzodiazepines Corresponding Author: Prof. Simon Gibbons, Corresponding Author's Institution: UCL School of Pharmacy First Author: Simon Gibbons Order of Authors: Simon Gibbons; Shruti Beharry Abstract: The purpose of this review is to identify emerging or new psychoactive substances (NPS) by undertaking an online survey of the UK NPS market and to gather any data from online drug fora and published literature. Drugs from four main classes of NPS were identified: psychostimulants, dissociative anaesthetics, hallucinogens (phenylalkylamine-based and lysergamide-based materials) and finally benzodiazepines. For inclusion in the review the 'user reviews' on drugs fora were selected based on whether or not the particular NPS of interest was used alone or in combination. NPS that were use alone were considered. Each of the classes contained drugs that are modelled on existing illegal materials and are now covered by the UK New Psychoactive Substances Bill in 2016. Suggested Reviewers: Title Page (with authors and addresses) An overview of Emerging and New Psychoactive Substances in the United Kingdom Shruti Beharry and Simon Gibbons1 Research Department of Pharmaceutical and Biological Chemistry UCL School of Pharmacy
    [Show full text]
  • Mephedrone Is a Class B Drug, Which Means Self-Referral Form and It Is Illegal to Possess, Sell Or Give Away
    THE LAW CONTACT INFORMATION Novel Psychoacve Substances (NPS) are If you would like support controlled substances under the Misuse of around your substance HMP BRISTOL Drugs Act (1971). use, please complete a Substance Misuse Team Mephedrone is a Class B drug, which means self-referral form and it is illegal to possess, sell or give away. return to Health Care. Possession can result in prosecuon and up PALS to a five year prison sentence or an unlimited fine. To make a comment, raise a concern Mephedrone or make a complaint, please contact the Trust’s Paent Advice and Liaison Supplying someone else, even your friends, Service (PALS). can result in a prison sentence of up to 14 Know the effects years or an unlimited fine. Tel: 01249 468261 Freephone: 0800 073 1778 Email: [email protected] Being convicted of a drug‐related offence could have a serious impact on your future. This could affect the types of jobs you apply for and stop you from entering certain OTHER FORMATS OR countries. LANGUAGES If you need this informaon in other formats (such as large print, Braille) or in another language, please call PALS Lead: Chris Eade Leaflet code: 326 Approval date: Aug 2014 Review due: Aug 2017 WHAT IS MEPHEDRONE EFFECTS THE RISKS Mephedrone is also known as The effects of mephedrone can vary and All drugs pose a risk of dependency and meow meow, meph, m‐cat and miaow can affect people differently. It is never can cause short and long‐term damage certain what effect it will have on the user.
    [Show full text]
  • Subchronic Continuous Phencyclidine Administration Potentiates Amphetamine-Induced Frontal Cortex Dopamine Release
    Neuropsychopharmacology (2003) 28, 34–44 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Subchronic Continuous Phencyclidine Administration Potentiates Amphetamine-Induced Frontal Cortex Dopamine Release Andrea Balla1, Henry Sershen1,2, Michael Serra1, Rajeth Koneru1 and Daniel C Javitt*,1,2 1 2 Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA; Department of Psychiatry, New York University School of Medicine, New York, NY, USA Functional dopaminergic hyperactivity is a key feature of schizophrenia. Etiology of this dopaminergic hyperactivity, however, is unknown. We have recently demonstrated that subchronic phencyclidine (PCP) treatment in rodents induces striatal dopaminergic hyperactivity similar to that observed in schizophrenia. The present study investigates the ability of PCP to potentiate amphetamine-induced dopamine release in prefrontal cortex (PFC) and nucleus accumbens (NAc) shell. Prefrontal dopaminergic hyperactivity is postulated to underlie cognitive dysfunction in schizophrenia. In contrast, the degree of NAc involvement is unknown and recent studies have suggested that PCP-induced hyperactivity in rodents may correlate with PFC, rather than NAc, dopamine levels. Rats were treated with 5–20 mg/kg/day PCP for 3–14 days by osmotic minipump. PFC and NAc dopamine release to amphetamine challenge (1 mg/kg) was monitored by in vivo microdialysis and HPLC-EC. Doses of 10 mg/kg/day and above produced serum PCP concentrations (50–150 ng/ml) most associated with PCP psychosis in humans. PCP-treated rats showed significant, dose-dependent enhancement in amphetamine-induced dopamine release in PFC but not NAc, along with significantly enhanced locomotor activity. Enhanced response was observed following 3-day, as well as 14-day, treatment and resolved within 4 days of PCP treatment withdrawal.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • 3,4-Methylenedioxymethcathinone (Methylone) [“Bath Salt,” Bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxymethcathinone (Methylone) [“Bath salt,” bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019 Introduction: discriminate DOM from saline. 3,4-Methylenedioxymethcathinone (methylone) is a Because of the structural and pharmacological similarities designer drug of the phenethylamine class. Methylone is a between methylone and MDMA, the psychoactive effects, adverse synthetic cathinone with substantial chemical, structural, and health risks, and signs of intoxication resulting from methylone pharmacological similarities to 3,4-methylenedioxymeth- abuse are likely to be similar to those of MDMA. Several chat amphetamine (MDMA, ecstasy). Animal studies indicate that rooms discussed pleasant and positive effects of methylone when methylone has MDMA-like and (+)-amphetamine-like used for recreational purpose. behavioral effects. When combined with mephedrone, a controlled schedule I substance, the combination is called User Population: “bubbles.” Other names are given in the above title. Methylone, like other synthetic cathinones, is a recreational drug that emerged on the United States’ illicit drug market in 2009. It is perceived as being a ‘legal’ alternative to drugs of Licit Uses: Methylone is not approved for medical use in the United abuse like MDMA, methamphetamine, and cocaine. Evidence States. indicates that youths and young adults are the primary users of synthetic cathinone substances which include methylone. However, older adults also have been identified as users of these Chemistry: substances. O H O N CH3 Illicit Distribution: CH O 3 Law enforcement has encountered methylone in the United States as well as in several countries including the Netherlands, Methylone United Kingdom, Japan, and Sweden.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]